Results 1 to 10 of about 394 (50)
: Objectives: Ceftolozane/tazobactam is a cephalosporin/β-lactamase inhibitor combination with activity against Gram-negative bacilli. Here we report the use of ceftolozane/tazobactam in Canada using a national registry. Methods: The CLEAR registry uses
George G. Zhanel +15 more
doaj +1 more source
Objective(s): The aim of this study was to conduct a meta-analysis to assess the clinical safety of ceftolozane-tazobactam for the treatment of acute bacterial infections in adult patients.
Li-Ting Wang +7 more
doaj +1 more source
Background: Ceftolozane-tazobactam is an emerging treatment for severe infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. However, limited data support its use in bacteremia treatment.
Hakeam A. Hakeam +10 more
doaj +1 more source
Ceftolozane-tazobactam is a cephalosporin/β-lactamase inhibitor combination developed for use against some β-lactam- and multidrug-resistant Gram-negative organisms.
J. Belkhair +5 more
doaj +1 more source
Background Extracorporeal membrane oxygenation (ECMO) is increasingly used in intensive care units and can modify drug pharmacokinetics and lead to under-exposure associated with treatment failure. Ceftolozane/tazobactam is an antibiotic combination used
Camille Mané +9 more
doaj +1 more source
Ceftolozane/tazobactam is approved for the treatment of patients from birth to
Emmanuel Roilides +7 more
doaj +1 more source
Background: The emergence of antibiotic resistance is increasing and there are few effective antibiotics to treat infections caused by resistant and multidrug resistant bacterial pathogens.
Felipe Francisco Tuon +4 more
doaj +1 more source
: Objectives: To report on the activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa isolates collected from hospitalized patients with pneumonia in US intensive care units (ICUs) between 2015 and 2018. Activity against all P.
Michael A. Pfaller +7 more
doaj +1 more source
Background Ceftolozane/tazobactam, a combination antibacterial agent comprising an anti-pseudomonal cephalosporin and β-lactamase inhibitor, is approved for the treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) in ...
Marin H. Kollef +7 more
doaj +1 more source
Background: Complicated urinary tract infection (cUTI) is often associated with drug-resistant pathogens and requires therapy with broad-spectrum antibiotics.
Guan-Jhou Chen +5 more
doaj +1 more source

